Dyne Therapeutics Inc (DYN)

Jul 28, 2026

Dyne Therapeutics Announces U.S. FDA Clearance of Investigational New Drug Application for DYNE-302 in Facioscapulohumeral Muscular Dystrophy - Investing News Network

Jul 28, 2026

Jul 28, 2026

Dyne Therapeutics receives FDA clearance for FSHD trial - Investing.com

Jul 28, 2026

Jul 28, 2026

Dyne Therapeutics Announces U.S. FDA Clearance of Investigational New Drug (IND) Application for DYNE-302 in Facioscapulohumeral Muscular Dystrophy (FSHD) - marketscreener.com

Jul 28, 2026

Jul 28, 2026

Dyne Targets FSHD, a Muscle Disease With No Approved Therapies - Stock Titan

Jul 28, 2026

Jul 28, 2026

Dyne Therapeutics Inc (DYN) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey

Jul 28, 2026

Jul 27, 2026

Dyne Therapeutics stock hits 52-week high at 25.06 USD By Investing.com - Investing.com UK

Jul 27, 2026

Jul 27, 2026

ForDyne B.V. (DYN) files Rule 144 to potentially sell 261,460 common shares - Stock Titan

Jul 27, 2026

Jul 27, 2026

Dyne Therapeutics stock hits 52-week high at 25.06 USD - Investing.com

Jul 27, 2026

Jul 27, 2026

Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com

Jul 27, 2026

Jul 27, 2026

Dyne Therapeutics Inc (DYN) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey

Jul 27, 2026

Jul 27, 2026

Dyne Therapeutics Inc (DYN) Institutional Confidence - TradingKey

Jul 27, 2026

Jul 27, 2026

Dyne Therapeutics Inc (DYN) Cash Flow - TradingKey

Jul 27, 2026

Jul 27, 2026

Dyne Therapeutics Inc (DYN) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey

Jul 27, 2026

Jul 27, 2026

Dyne Therapeutics Inc (DYN) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey

Jul 27, 2026

Jul 27, 2026

Dyne Therapeutics Inc (DYN) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey

Jul 27, 2026

Jul 27, 2026

Dyne Therapeutics Inc (DYN) Valuation: PE, PB & Fair Value Analysis - TradingKey

Jul 27, 2026

Jul 26, 2026

Why DYN Shares Are Down 10% After-Hours? Day After An FDA Win, Another Announcement Rocks Stock - Stocktwits

Jul 26, 2026

Jul 26, 2026

Dyne Therapeutics Announces Pricing Of Upsized $375 Million Public Offering - Pulse 2.0

Jul 26, 2026

Jul 26, 2026

DYN Stock Gains As It Gears Up For Accelerated Approval Of DMD Therapy: Wall Street Sees 140% Upside - Stocktwits

Jul 26, 2026

Jul 25, 2026

TradingKey - TradingKey

Jul 25, 2026

Jul 24, 2026

Skorney: FDA's Sarepta Precedent Makes Dyne DMD Approval 'Impossible' to Deny - finance.biggo.com

Jul 24, 2026

Jul 24, 2026

Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - TradingView

Jul 24, 2026

Jul 24, 2026

Dyne Therapeutics Grants New Hires Options on Up to 358,600 Shares - Stock Titan

Jul 24, 2026

Jul 24, 2026

Dyne Therapeutics grants inducement equity awards for 475,100 shares to 12 new hires - Bitget

Jul 24, 2026

Jul 23, 2026

DYN Initiated Coverage On by Cantor Fitzgerald -- Rating Set to Overweight - GuruFocus

Jul 23, 2026

Jul 23, 2026

Dyne Therapeutics closes $431.4 million stock offering By Investing.com - Investing.com South Africa

Jul 23, 2026

Jul 23, 2026

Dyne Therapeutics Upsized Equity Offering Strengthens Cash Runway - The Globe and Mail

Jul 23, 2026

Jul 23, 2026

Dyne Therapeutics closes $431.4 million stock offering - Investing.com

Jul 23, 2026

Jul 23, 2026

Dyne Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares - The Manila Times

Jul 23, 2026

Jul 23, 2026

Dyne Therapeutics Sells 21M Shares at $20.50 in Offering - Stock Titan

Jul 23, 2026

Jul 23, 2026

Dyne a new overweight at Cantor on platform for neuromuscular disorders - Seeking Alpha

Jul 23, 2026

Jul 23, 2026

DYN: Dyne Therapeutics Inc Latest Stock Price, Analysis, News and Trading Ideas - Stocktwits

Jul 23, 2026

Jul 23, 2026

Cantor Fitzgerald initiates Dyne Therapeutics stock with overweight rating By Investing.com - Investing.com Canada

Jul 23, 2026

Jul 23, 2026

Dyne Therapeutics (DYN) Prices Upsized Share Offering, Is The Valuation Still Compelling? - Yahoo Finance

Jul 23, 2026

Jul 23, 2026

Dyne Therapeutics closes upsized public offering of 21,045,000 shares at $20.5 each - Bitget

Jul 23, 2026

Jul 22, 2026

Form 424B5 Dyne Therapeutics Inc For: 22 July By Investing.com - Investing.com South Africa

Jul 22, 2026

Jul 22, 2026

Dyne Therapeutics stock falls 9% after pricing stock offering - Investing.com

Jul 22, 2026

Jul 22, 2026

Dyne Therapeutics Launches 18.3M-Share Offering at $20.50; Nets ~$352M, Greenshoe to $405M - TradingView

Jul 22, 2026

Jul 22, 2026

Analysts Are Bullish on These Healthcare Stocks: Dyne Therapeutics (DYN), ACADIA Pharmaceuticals (ACAD) - The Globe and Mail

Jul 22, 2026

Jul 22, 2026

Dyne Therapeutics shares slide after pricing $375 million public offering (NASDAQ:DYN) - MSN

Jul 22, 2026

Jul 22, 2026

Why Dyne Therapeutics (DYN) Stock Is Down Today - Moomoo

Jul 22, 2026

Jul 22, 2026

Dyne Therapeutics (DYN) Upsizes Public Offering to $375.15M Amid Stock Decline - GuruFocus

Jul 22, 2026

Jul 22, 2026

SRPT Stock Slides 10% in a Week: Is Dyne Therapeutics a Threat? - The Globe and Mail

Jul 22, 2026

Jul 22, 2026

Pegasystems Posts Downbeat Q2 Results, Joins Adtran, Dyne Therapeutics And Other Big Stocks Moving Lower - Benzinga

Jul 22, 2026

Jul 22, 2026

symbol__ Stock Quote Price and Forecast - CNN

Jul 22, 2026

Jul 22, 2026

Why is Dyne Therapeutics stock sliding today? By Investing.com - Investing.com Canada

Jul 22, 2026

Jul 22, 2026

Dyne Therapeutics stock falls 9% after pricing stock offering By Investing.com - Investing.com Canada

Jul 22, 2026